T
he Manifesto Pare (People with arthritis and rheumatism in Europe) leads from March 29 until May 6 next to a study at European level on these two diseases to better understand the people who are suffering and improve services are available to them.Seven countries will be studied with funding from pharmaceutical group AstraZeneca (France, Germany, Hungary, the Netherlands, Italy, Sweden and United Kingdom).
"103 million Europeans are affected," said Neil Betteridge, president of the steering group of Pare, in a press release.
Of all the durable diseases, those that affect the largest number of people. "A french three would be affected by these diseases" often neglected ".
Established in January 2001, the Manifesto Pare aims to promote the exchange of information between patients to improve access to treatment, the relationship between patients and doctors and public awareness and authorities.
The results will be presented at the conference of the European league against rheumatism (Eular) in Berlin next June.
Related post :
- New Treatment Of Rheumatoid Arthritis With Anti-Inflammatory Exosomes
- Launching A Program To Manage Arthritis At Work
- To Treat Canine Arthritis, A Possible Solution
- Galapagos, J & J in Potential Arthritis $ 1 Billion Deal
- Arthritis Drug : The United Kingdom Suspended Prexige
- The Mast : Key Cells In Inflammatory Arthritis Development
- First Case Of Arthritis In Japan
No comments:
Post a Comment